NCCN publishes patient resource for small bowel adenocarcinoma

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

The National Comprehensive Cancer Network updated its chronic myeloid leukemia treatment guidelines, recommending Scemblix (asciminib) for the treatment of adults with newly diagnosed Ph+ CML-CP as a category 1-preferred.

November 22, 2024

Vol.50 No.44

Drugs & Targets

NCCN adds Lymphir to Clinical Practice Guidelines in Oncology

The National Comprehensive Cancer Network added Lymphir (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy, to the NCCN Clinical Practice Guidelines in Oncology. Lymphir is included based on an NCCN Category 2A recommendation which indicates a uniform NCCN consensus that the drug is appropriate as an option for patients with CTCL.

September 06, 2024

Vol.50 No.33

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.

NCCN patient resources receive Hemes Creative Award, Communicator Award, Viddy Award

The National Comprehensive Cancer Network announced recognitions for the award-winning library of NCCN Guidelines for Patients and NCCN Patient Webinars.

June 21, 2024

Vol.50 No.25

Clinical Roundup

NCCN and Polish oncology groups to adapt NCCN Guidelines for Poland

The National Comprehensive Cancer Network took part in two events in Warsaw focused on advancing cancer care and highlighting the Poland-US bilateral achievements in health care May 21-22.

May 24, 2024

Vol.50 No.21

In Brief

Daniel Geynisman named editor-in-chief of JNCCN

Daniel M. Geynisman was named the editor-in-chief of JNCCN—Journal of the National Comprehensive Cancer Network.

May 17, 2024

Vol.50 No.20

NCCN publishes patient resource for small bowel adenocarcinoma

YOU MAY BE INTERESTED IN

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

NCCN adds Lymphir to Clinical Practice Guidelines in Oncology

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

NCCN patient resources receive Hemes Creative Award, Communicator Award, Viddy Award

NCCN and Polish oncology groups to adapt NCCN Guidelines for Poland

Daniel Geynisman named editor-in-chief of JNCCN

Renew today!

Subscriber content

Never miss an issue!

Login

NCCN publishes patient resource for small bowel adenocarcinoma

YOU MAY BE INTERESTED IN

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

NCCN adds Lymphir to Clinical Practice Guidelines in Oncology

Platinum drugs are off the shortage list, but the underlying problem is unsolvedFDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

NCCN patient resources receive Hemes Creative Award, Communicator Award, Viddy Award

NCCN and Polish oncology groups to adapt NCCN Guidelines for Poland

Daniel Geynisman named editor-in-chief of JNCCN

Never miss an issue!

Login

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”